[1]Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17:93-110. [2]康锦钰,罗佳,高泽天,等. 胆汁淤积性肝损伤炎性反应机制的研究进展[J]. 基础医学与临床, 2022,42: 809-813. [3]杨敏,张钧. 原发性胆汁性胆管炎的诊断和预后研究进展[J]. 临床检验杂志, 2021,39: 841-844. [4]Jing W, Liu J, Liu M. The global trends and regional differences in incidence of HEV infection from 1990 to 2017 and implications for HEV prevention[J]. Liver Int, 2021, 41:58-69. [5]Aslan AT, Balaban HY. Hepatitis E virus: epidemiology, diagnosis, clinical manifestations, and treatment[J]. World J Gastroenterol, 2020, 26:5543-5560. [6]Whitsett M, Feldman DM, Jacobson I. Hepatitis E virus infection in the United States: current understanding of the prevalence and significance in the liver transplant patient population and proposed diagnostic and treatment strategies[J]. Liver Transpl, 2020, 26:709-717. [7]Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis[J]. Lancet Gastroenterol Hepatol, 2020, 5:306-315. [8]韩琳,梁庆升,谢欢,等. 基线IgM水平对原发性胆汁性胆管炎治疗应答的预测价值[J]. 临床肝胆病杂志, 2022,38: 815-820. [9]郑微,姜菲菲,单晶,等. 原发性胆汁性胆管炎中IgG亚型分布特征分析[J]. 北京医学, 2021,43: 207-210. [10]Jiang X, Wang Y, Su Z, et al. Red blood cell distribution width to platelet ratio levels in assessment of histologic severity in patients with primary biliary cholangitis[J]. Scand J Clin Lab Invest, 2018, 78:258-263. [11]张唯,舒婷,宋小敏,等. 敲除IgG受体FcγRIIB加重小鼠全身及脂肪组织炎性反应[J]. 基础医学与临床. 2018,38: 938-943. [12]Gerussi A, Halliday N, Saffioti F, et al. Normalization of serum immunoglobulin G levels is associated with improved transplant-free survival in patients with autoimmune hepatitis[J]. Dig Liver Dis, 2020, 52:761-767. [13]Weill JC, Reynaud CA. IgM memory B cells: specific effectors of innate-like and adaptive responses[J]. Curr Opin Immunol, 2020, 63:1-6. doi: 10.1016/j.coi.2019.09.003. |